Viatris

Viatris

Yahoo Finance • 20 days ago

Healthcare August recap: Moderna jumps 156% as biotech shines; DaVita sinks

[Health Care Medical Concept] ogichobanov/iStock via Getty Images The healthcare sector (XLV [https://seekingalpha.com/symbol/XLV]) gained 4.91% in August, outperforming the broader S&P 500 (SPY [https://seekingalpha.com/symbol/SPY]), whi... Full story

Yahoo Finance • 23 days ago

Billionaire Portfolios: 2 Under-$20 Healthcare Stock Picks

The recent breakout of Moderna reminded investors that AI stocks aren't the only destination to make money. Healthcare and biotech stocks offer promising long-term opportunities if chosen wisely. We ran an analysis based on Insider Monkey... Full story

Yahoo Finance • last month

3 S&P 500 Stocks We Keep Off Our Radar

3 S&P 500 Stocks We Keep Off Our Radar The S&P 500 (^GSPC) is often seen as a benchmark for strong businesses, but that doesn't mean every stock is worth owning. Some companies face significant challenges, whether it's stagnating growth,... Full story

Yahoo Finance • last month

Winners And Losers Of Q2: ANI Pharmaceuticals (NASDAQ:ANIP) Vs The Rest Of The Generic Pharmaceuticals Stocks

Winners And Losers Of Q2: ANI Pharmaceuticals (NASDAQ:ANIP) Vs The Rest Of The Generic Pharmaceuticals Stocks Quarterly earnings results are a good time to check in on a company's progress, especially compared to its peers in the same sec... Full story

Yahoo Finance • last month

Viatris (VTRS) Q2 2026 Earnings Call Transcript

Image source: The Motley Fool. DATE Thursday, August 6, 2026 at 8:30 a.m. ET CALL PARTICIPANTS CEO - Scott SmithInterim CFO - Paul CampbellChief R&D Officer - Philippe MartinChief Commercial Officer - Corinne Le GoffHead of Capital Mar... Full story

Yahoo Finance • 2 months ago

Viatris (VTRS) Stock Sees Modest Fair Value Lift After Q1 Results And Pipeline Progress

Find your next quality investment with Simply Wall St's easy and powerful screener, trusted by over 7 million individual investors worldwide. The latest research on Viatris centers on a revised price target of US$22 per share and what tha... Full story

Yahoo Finance • 2 months ago

Earnings scorecard: eight out of nine healthcare companies deliver EPS wins this week

Healthcare stocks (XLV [https://seekingalpha.com/symbol/XLV]) grabbed the spotlight this week as Wall Street digested earnings reports from companies including Centene (CNC [https://seekingalpha.com/symbol/CNC]), DexCom (DXCM [https://seek... Full story

Yahoo Finance • 2 months ago

3 Healthcare Stocks We Keep Off Our Radar

3 Healthcare Stocks We Keep Off Our Radar Healthcare companies are pushing the status quo by innovating in areas like drug development and digital health. Players catalyzing medical advancements have benefited from elevated demand, and th... Full story

Yahoo Finance • 2 months ago

Stock index futures edge higher as investors seek rebound after Thursday selloff

[Wall Street New York stock exchange stock market] alexsl Stock index futures were higher on Friday as the stock market hoped to recover from Thursday's selloff. Dow futures (INDU [https://seekingalpha.com/symbol/INDU]) +0.33%, S&P 500... Full story

Yahoo Finance • 2 months ago

Financial Stocks Rally To New Highs. JPMorgan Is One Of Them.

JPMorgan Chase stock and two other financial names hit new highs. A pharmaceutical stock also reached a high and is in a buy zone. Continue Reading... Full story

Yahoo Finance • 3 months ago

Novartis vs. Teva: Which Pharmaceutical Stock Is a Better Buy in 2026?

Choosing between Novartis AG (NYSE:NVS) and Teva Pharmaceutical Industries (NYSE:TEVA) requires weighing the stability of an established innovator against the potential of a generic specialist undergoing a significant turnaround. Novartis... Full story

Yahoo Finance • 3 months ago

3 Dirt Cheap Healthcare Shares Under $30 to Buy Right Now

Quick Read Pfizer's 7% yield and forward P/E of 8 complement Viatris's three FDA PDUFA decisions arriving before year-end 2026. Kimberly-Clark's pending acquisition of Kenvue at $3.50 cash plus shares gives holders a defined takeout floor... Full story

Yahoo Finance • 3 months ago

Eli Lilly and vs. Teva: Which Pharmaceutical Stock Is a Better Buy in 2026?

Key Points Eli Lilly and dominance in weight loss and diabetes treatments continues to fuel massive revenue growth. Teva Pharmaceutical Industries offers a value-oriented play as it moves past legal hurdles and expands its biosimilar port... Full story

Yahoo Finance • 3 months ago

Viatris (VTRS) Secures Loan Amid Positive Phase 3 Results

Viatris Inc. (NASDAQ:VTRS) is one of the Top 10 Extreme Value Stocks To Buy Now. On July 1, Viatris Inc. (NASDAQ:VTRS) entered into a loan agreement with a group of lenders led by Mizuho Bank. The company secured a ¥40 billion senior unsec... Full story

Yahoo Finance • 3 months ago

ISCV vs. IWN: Which Small-Cap Value ETF Is the Better Buy?

While both funds target smaller U.S. companies that appear undervalued relative to the broader market, the iShares Morningstar Small-Cap Value ETF (NYSEMKT:ISCV) provides that exposure to the small-cap value space at a lower cost than the... Full story

Yahoo Finance • 3 months ago

1 Cash-Producing Stock with Exciting Potential and 2 Facing Headwinds

1 Cash-Producing Stock with Exciting Potential and 2 Facing Headwinds A company that generates cash isn't automatically a winner. Some businesses stockpile cash but fail to reinvest wisely, limiting their ability to expand. Luckily for y... Full story

Yahoo Finance • 3 months ago

Viatris Recognized as One of the 2026 Best Workplaces™ in Canada

ETOBICOKE, ON, June 16, 2026 /PRNewswire/ -- Viatris Inc. (Nasdaq: VTRS) has been recognized as one of the 2026 Best Workplaces™ in Canada by Great Place to Work®. This recognition highlights Viatris' commitment to fostering a culture wher... Full story

Yahoo Finance • 3 months ago

Lexicon Pharmaceuticals vs. Pfizer: Which Drugmaker Stock Is a Better Buy in 2026?

Investors deciding between Lexicon Pharmaceuticals(NASDAQ:LXRX) and Pfizer(NYSE:PFE) face a choice between an emerging high-growth biotech player and an established global pharmaceutical titan with massive scale. These two companies opera... Full story

Yahoo Finance • 4 months ago

Q4 Earnings Highlights: Amneal (NASDAQ:AMRX) Vs The Rest Of The Generic Pharmaceuticals Stocks

Quarterly earnings results are a good time to check in on a company’s progress, especially compared to its peers in the same sector. Today we are looking at Amneal (NASDAQ:AMRX) and the best and worst performers in the generic pharmaceutic... Full story

Yahoo Finance • 4 months ago

Acute Myocardial Infarction Market is Expected to Hit Growth Stride at a CAGR of 13% During the Forecast Period (2026-2036) with New Therapeutic Innovations | DelveInsight

The acute myocardial infarction market is experiencing steady growth driven by rising global cardiovascular disease prevalence and expanding geriatric populations. Advances in diagnostic technologies and rapid-acting therapies are accelera... Full story